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Abstract
Background—Atopic asthmatic patients are reported to be more sensitive to the effects of
environmental endotoxin (LPS) than healthy volunteers (HVs). It is unknown whether this
sensitivity is due to dysregulated inflammatory responses after LPS exposure in atopic asthmatic
patients.
Objective—We sought to test the hypothesis that atopic asthmatic patients respond differentially
to inhaled LPS challenge compared with HVs.
Methods—Thirteen allergic asthmatic (AA) patients and 18 nonallergic nonasthmatic subjects
(healthy volunteers [HVs]) underwent an inhalation challenge to 20,000 endotoxin units of
Clinical Center Reference Endotoxin (LPS). Induced sputum and peripheral blood were obtained
at baseline and 6 hours after inhaled LPS challenge. Sputum and blood samples were assayed for
changes in inflammatory cell numbers and cytokine and cell-surface marker levels on monocytes
and macrophages.
Results—The percentage of neutrophils in sputum (%PMN) in induced sputum similarly and
significantly increased in both HVs and AA patients after inhaled LPS challenge. However, the
absolute numbers of leukocytes and PMNs recruited to the airways were significantly lower in AA
patients compared with those seen in HVs with inhaled LPS challenge. Sputum levels of IL-6 and
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TNF-α were significantly increased in both cohorts, but levels of IL-1β and IL-18 were only
significantly increased in the HV group. Cell-surface expression of Toll-like receptors 4 and 2
were significantly enhanced only in the HV group.
Conclusions—The airway inflammatory response to inhaled LPS challenge is blunted in AA
patients compared with that seen in HVs and accompanied by reductions in airway neutrophilia
and inflammasome-dependent cytokine production. These factors might contribute to increased
susceptibility to airway microbial infection or colonization in AA patients.
Keywords
Asthma; LPS; induced sputum; inflammasome; innate immunity
The majority of asthma exacerbations are triggered by viral infections, pollutants that can
injure or activate airway epithelial cells, or bioaerosols, which likely activate airway
monocytes and macrophages.1-3 Endotoxin (LPS) is a pathogen-associated molecular pattern
found in the outer layer of gram-negative bacteria and is an important component of ambient
air particulate matter,4,5 tobacco smoke, and particulates in occupational and domestic
environments.6,7
Inhaled LPS interacts with the cell-surface receptors CD14 and Toll-like receptor (TLR) 4
and activates airway macrophages, which in turn induce neutrophilic inflammation of the
airways. In healthy volunteers (HVs) and allergic asthmatic (AA) patients, LPS inhalation
has also been found to increase expression of CD11b and CD14 in airway monocytes and
macrophages8-10 and increase levels of pro–IL-1β in airway macrophages.11 It has been
reported that asthmatic patients are more sensitive to the effect of LPS exposure than
HVs.9,12 We have observed that monocytes and macrophages from AA patients have
increased expression of CD14 and that this factor correlates with airway eosinophilia and
neutrophilic response to LPS,8 suggesting that asthmatic airway cells can be primed to
respond to LPS challenge.
However, recent work has also shown that asthmatic patients might exhibit defective innate
immune responses to microbes. Mycoplasma and Chlamydia species have been recovered
from airway samples of both adult and pediatric asthmatic patients,13,14 thus making the use
of macrolide antibiotics more popular for the treatment of asthma exacerbations and hard-to-
control asthma.15 Large-scale epidemiologic studies have shown that asthmatic patients are
at increased risk of airway infection with organisms such as Streptococcus pneumoniae16-19
compared with HVs. In addition, the airways of asthmatic patients have a different
microbiome than those of healthy control subjects, with evidence of increased bacterial
diversity20 and the presence of Haemophilus species21 in asthmatic patients.
It is presently unknown whether either the degree or character of response to microbial
challenge is different between AA patients and HVs. In this study we undertook an initial
test of the hypothesis that AA patients respond differentially to LPS versus HVs by
comparing the airway inflammatory response of these 2 groups to inhalation challenge with
a 20,000 endotoxin units (EU) dose of Clinical Center Reference Endotoxin (CCRE; LPS).
Our primary end point was the percentage of neutrophils recovered from induced sputum
after LPS inhalation. We undertook an exploratory analysis of end points focused on sputum
neutrophil numbers, monocyte/macrophage surface marker expression, and sputum
supernatant cytokine concentrations. We also examined changes in circulating leukocyte and
blood neutrophil numbers after LPS challenge.
Hernandez et al. Page 2















Eighteen HVs and 13 AA patients completed this study (Table I). HVs had normal baseline
lung function (FEV1 percent predicted >80% and FEV1/forced vital capacity [FVC] ratio >
0.75), a negative allergy skin test result,22 and a negative methacholine challenge result.23
AA patients had lung function consistent with no more than mild episodic or mild persistent
asthma (FEV1 percent predicted > 80% and FEV1/FVC ratio > 0.70 without use of broncho-
dilating medications for 12 hours) but a history of episodic wheezing, chest tightness, or
shortness of breath after age 6 years consistent with asthma or physician-diagnosed asthma
after age 6 years. AA patients also had a positive methacholine test result (PC20 < 10 mg/
mL) and a positive allergy skin test result. See the Methods section in this article's Online
Repository at www.jacionline.org for specific details pertaining to skin test procedures.
Informed written consent was obtained from all subjects before their participation in the
study, which was approved by the Biomedical Institutional Review Board of the University
of North Carolina at Chapel Hill. This study was also reviewed and approved by the Data
Safety and Monitoring Board of the National Institute of Allergy and Infectious Diseases
(NIAID) and the US Food and Drug Administration (IND-BB-9998). The study was listed
on clinicaltrials.gov as NCT00839124.
Study design
All subjects were studied on 5 days: a baseline visit, a prechallenge visit the day before the
LPS challenge, an LPS challenge study visit, a 24-hour follow-up visit, and a final visit.
During the subject's baseline visit, we measured vital signs, spirometry, and exhaled nitric
oxide (eNO) levels, followed by venipuncture and sputum induction. At least 3 days
separated the baseline visit and the LPS challenge study visit. After the inhaled LPS
challenge, subjects were monitored for spirometry, vital signs, oxygen saturation, and
symptom score measurement at the following intervals after challenge: 30 and 60 minutes
and then hourly for 3 additional hours. At 6 hours after LPS challenge, we measured eNO
levels, followed by venipuncture for blood end points, and sputum induction. See Table E1
in this article's Online Repository at www.jacionline.org for specific procedures related to
each study visit.
Inhaled endotoxin challenge
CCRE (referred to as LPS) was provided by the National Institutes of Health Clinical
Center. A dose of 20,000 EU was previously shown to induce sputum neutrophilia and was
demonstrated to be safe and well tolerated in previous studies.24 Subjects inhaled LPS
through a DeVilbiss Ultraneb 99 ultrasonic nebulizer (DeVilbiss Healthcare, Somerset, Pa).
Induced sputum was obtained 6 hours after LPS inhalation and processed as previously
described.4,25-27
Induced sputum assessments
The procedure for sputum induction has been described in detail previously4 and is also
included in the Methods section in this article's Online Repository. Subjects had to have
previously demonstrated the ability to produce a sputum sample with at least 250,000 cells
during a general screening visit. Cell viability (trypan blue exclusion) and total cell counts
were assessed in a Neubauer hemocytometer (Hausser Scientific, Horsham, Pa), and
differential cell counts were performed on cytocentrifuged cells stained with a modified
Wright stain (Hema-Stain-3; Fisher Scientific, Waltham, Mass). Some of the cells were
immediately used for flow cytometric assays.
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Expression of selected cell-surface molecules on sputum leukocytes was quantified by using
multicolor flow cytometry with a BD LSR-II flow cytometer (BD Immunocytometry
Systems, San Jose, Calif), as previously described.28 These included molecules associated
with antigen presentation and specific immunity (CD86/B7.2 and HLA-DR/MHC-II), as
well as innate immune function (CD11b/CR3 and CD14/LPS receptor). Upregulation or
downregulation of specific surface molecules was quantified as a change in the mean
fluorescence intensity of the gated population. Fluorochrome-labeled antibodies were
obtained from BD Biosciences (CD11b–phycoerythrin-CY5, CD45–allophycocyanin-Cy7,
and HLA-DR–peridinin-chlorophyll-protein complex) and Beckman Coulter (Fullerton,
Calif; CD14-allophycocyanin and CD86-phycoerythrin). Appropriate, nonspecific, labeled
isotypic control antibodies were also obtained from these sources.
Mediator measurement
Cytokines from sputum supernatants were measured by using multiplex technology
(MesoScaleDiscovery/MSD, Gaithersburg, Md). Each sample was analyzed with the Human
TH1/TH2 7-Plex Ultra-Sensitive Kit (IFN-γ, IL-10, IL-12 p70, IL-13, IL-2, IL-4, and IL-5)
and the Human ProInflammatory-4 II Ultra-Sensitive Kit (IL-1β, IL-6, IL-8, and TNF-α;
both from MesoScale-Discovery/MSD). All supernatant samples were diluted 1:4 and had a
final dithiothreitol concentration of less than 1 mmol/L, at which no deleterious effects have
been observed with the MSD platform. Sputum supernatants were also analyzed for IL-18
by using the Invitrogen (Carlsbad, Calif) Human ELISA IL-18 kit (KHC0181), according to
the manufacturer's instructions, with 12.5 pg/mL as the lowest level of detection.
Exhaled nitric oxide measurement
Measurements of nitric oxide in the lower airways (exhaled nitric oxide [eNO]) were
performed by using an online Sievers Nitric Oxide Analyzer (GE Analytical Instruments,
Boulder, Colo). The system is a semiautomatized collection technique using a method
recommended by the European Respiratory and the American Thoracic Society (2005). The
flow rate was 50 mL/s.
Conditional power analysis of the primary end point (post-LPS percentage of PMNs)
This study was designed to test the hypothesis that the AA and HV groups would differ in
the degree of neutrophilic inflammation present in sputum (expressed as the percentage of
neutrophils in sputum [%PMN] as the primary end point) after LPS challenge. Our initial
sample size estimate was based on measures of variability of the %PMN from prior studies
of AA and HV cohorts using different sources and doses of LPS, which indicated that 18 in
each group would provide adequate statistical power for this study. A conditional power
analysis was planned after 10 HVs and 10 AA patients had been recruited to ensure that our
initial estimate was appropriate. However, HV recruitment was already completed (n = 18)
when sputum data from AA volunteers 9 to 13 (providing n ≥ 10 AA) became
contemporaneously available, resulting in an interim analysis based on data from 18 HVs
and 13 HVs. The conditional power analysis is described in the Results section in this
article's Online Repository at www.jacionline.org, and after review by the NIAID's Data
Safety Monitoring Board, recruitment was suspended with 18 HVs and 13 AA volunteers.
Statistical analysis of other sputum end points
For all responses, including %PMNs, the cellular response to LPS expressed as the change
from baseline in total leukocyte numbers (cells per milligram), neutrophil response (PMNs
per milligram) in sputum, and the remaining exploratory measures, such as circulating cell
counts, sputum cytokine concentrations, and cell-surface marker expression of sputum cells,
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we used the following strategy to assess the LPS challenge effects. The effects within a
group (either HVs or AA patients) were evaluated through paired testing of the difference
between the baseline values (pre-LPS challenge values) and post-LPS challenge values. The
effects of LPS challenge between the AA and HV groups were evaluated by using a 2-
sample test comparing the postchallenge-prechallenge difference in AA patients with the
postchallenge-prechallenge differences in HVs. Proper transformations to those responses
were conducted to normalize the data. The reported results are based on nonparametric
paired t tests (the Wilcoxon signed-rank rest) for the changes within each group and
nonparametric t tests (the Mann-Whitney test) for between-group comparisons at the
nominal level of .05.
RESULTS
Subjects’ demographics
Twenty-one HVs and 17 AA patients were enrolled in this study. Of these, 18 HVs and 13
patients with mild intermittent AA completed the study. HVs were withdrawn for abnormal
baseline complete blood cell counts with differential, recent viral illness, or smoking. AA
patients were withdrawn for abnormal baseline spirometric results (FEV1/FVC ratio < 0.70),
hypertension, or baseline abnormal complete blood cell counts with differential.
Demographics for those completing the study are shown in Table I. All subjects who
completed the study tolerated the inhaled LPS challenge without significant changes in vital
signs, symptom scores, or decrements in spirometric results (data not shown).
Sputum neutrophilia (%PMNs)
The primary end point for this study was the %PMN present after LPS challenge, with our
original expectation that AA patients would have increased sputum neutrophilia after LPS
challenge compared with that seen in HVs. We found that %PMNs significantly increased in
both the HV and AA groups after LPS challenge; however, the post-LPS challenge %PMNs
were significantly lower in the AA patients compared with the HVs (Fig 1). Baseline
%PMNs of AA patients were also lower than those of HVs (P = .06). However, there was no
significant difference between groups (P = .9522) in %PMNs that increased with LPS
challenge (post-LPS minus pre-LPS %PMNs).
Other sputum and circulating cellularity end points
Although %PMNs increased after LPS challenge in both groups, the total number of cells in
sputum (expressed as cells per milligram of sputum; Fig 2, A) and neutrophils in sputum
(expressed as PMNs per milligram of sputum; Fig 2, B) were increased only in the HV
group after LPS challenge. To further characterize the degree of the cellular response, we
compared the difference between the post-LPS cell count and the baseline cell count (post-
LPS minus pre-LPS values) between the cohorts, finding that HVs had significantly greater
increases in both total sputum cell (P = .0009) and neutrophil (P = .003) numbers than AA
patients after inhaled LPS challenge. eNO values and numbers of eosinophils per milligram
at baseline were significantly increased in the AA patients compared with the HVs (Table I)
but were not changed with LPS challenge.
We next examined the response of circulating cells to determine whether there was a
systemic difference between the 2 cohorts consistent with the difference in induced sputum
responses with LPS challenge. Both cohorts significantly increased their total white blood
cell (WBC) counts (Fig 2, C) and absolute neutrophil counts (Fig 2, D) after inhaled LPS
challenge. However, the baseline WBC and absolute neutrophil counts in this cohort of AA
patients was lower compared with the baseline WBC (P = .01) and absolute neutrophil (P = .
004) counts in HVs. We also found decreased absolute neutrophil numbers in the blood after
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LPS challenge in AA patients compared with HVs (P = .04). This result suggests that this
cohort of AA patients responded systemically to LPS, although this response is not as robust
as that seen in HVs.
We randomly selected 5 samples each from the HV and AA cohorts for LPS assessments of
induced sputum (pre-LPS vs post-LPS) by using a limulus assay performed at our tissue
culture facility. We found no significant differences between the HVs and AA patients in
either baseline levels of LPS or post-CCRE challenge LPS levels (data not shown).
Induced sputum cytokines
We next explored why the AA cohort had decreased induced sputum cell and neutrophil
counts compared with those seen in HVs by examining cytokine concentrations in the
sputum super-natant samples that represent LPS signaling through TLR4. We found that
both HVs and AA patients had significant increases in both TNF-α and IL-6 concentrations
in induced sputum after LPS challenge (Fig 3, A and B). However, only HVs had significant
increases in levels of the inflammasome-dependent cytokines IL-1β and IL-18 with LPS
challenge (Fig 3, C and D). There were no differences with LPS challenge in either cohort in
levels of IL-8, IL-4, IL-5, or IL-13 (data not shown). These data suggest that LPS signaling
through TLR4 is preserved in both groups but that inflammasome-dependent processing of
IL-1β and IL-18 might be impaired in AA patients after inhaled LPS challenge.
Macrophage surface marker expression
LPS is known to interact with TLR4 and CD14 to initiate proinflammatory cytokine
signaling. We have previously shown increased surface marker expression of CD14 in HVs
and AA patients after inhaled LPS challenge.24,27 We examined surface marker expression
on both induced sputum monocytes (thought to be newly recruited cells to the airway) and
macrophages in 13 HVs and 7 AA patients. We found no significant change in monocyte
TLR4 surface expression with LPS challenge (Fig 4, A) but did find significant increases in
monocyte CD14 abundance after LPS challenge in both groups (Fig 4, B). In macrophages
we found increases in TLR4, TLR2, and CD11b levels (Fig 4, C-F) in HVs but not in AA
patients. We found no significant changes in macrophage CD14 expression with LPS
challenge in either cohort (Fig 4, D). We also noted increased (although not significantly)
surface expression of baseline TLR4 in monocytes and macrophages of AA patients and
significantly increased expression of TLR2 on sputum macrophages of AA patients (Fig 4,
E).
DISCUSSION
In this open-label study 18 HVs and 13 AA patients underwent an inhaled LPS challenge
with 20,000 EU of CCRE. We originally hypothesized that AA patients would have
exaggerated inflammatory responses to LPS compared with HVs. Previous data suggested
that (1) AA patients have increased levels of CD14 after inhaled allergen challenge29; (2)
LPS induces airway neutrophilia, correlating with increased levels of CD14 expression on
airway macrophages8; and (3) CD14 expression correlates with eosinophil numbers in the
airways8 and pretreatment of allergic inflammation with fluticasone decreases surface
monocyte CD14 levels and PMN responses to 20,000 EU CCRE.8 After inhaled LPS
challenge, both cohorts showed increases in %PMNs recruited to the airway. The final
%PMNs present after LPS challenge were significantly less in AA patients than in HVs, but
AA patients had reduced %PMNs at baseline compared with those seen in HVs, with no
significant difference in the %PMNs recruited to the airway when comparing HVs and AA
patients. There was augmentation of the proinflammatory cytokines IL-6 and TNF-α and
increases in sputum monocyte CD14 expression in both groups.
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However, there were clear differences between HVs and AA patients when examining the
absolute numbers of cells (cells per milligram of sputum) recruited to the airway with LPS
challenge. AA patients had increased airway eosinophilic inflammation at baseline, which
was not significantly modified by LPS challenge. Compared with HVs, AA patients had
reduced numbers of total leukocytes and neutrophils recovered from induced sputum with
inhaled LPS challenge. AA patients also had decreased numbers of WBCs and neutrophils
in the peripheral blood at baseline, as well as decreased post-LPS WBC and PMN counts. In
AA patients decreases in circulating leukocyte numbers at baseline might account for
decreased airway PMN counts after LPS challenge. TLR4/CD14-mediated signaling appears
to be similar in the AA and HV groups because they mounted similar sputum TNF-α and
IL-6 responses with LPS. However, we could not detect significant increases in the levels of
IL-1β or IL-18 in sputum from AA patients in contrast to increases seen in HVs. Recent data
from our group demonstrated decreased inflammasome gene expression in sputum
inflammatory cells from patients with atopic asthma compared with HVs.30 Further
examination of induced sputum macrophages with larger sample sizes will have to be
performed to determine whether AA patients produce less pro–IL-1β and pro–IL-18 than
HVs, whether activation of the P2X7 receptor (that then activates the inflammasome) is
altered in AA patients after LPS challenge, and/or whether cleavage of these proforms into
the mature soluble forms is impaired in AA patients compared with HVs. Previous work by
our group did show a 16-fold increase in pro–IL-1β mRNA in an allergic cohort consisting
of both asthmatic and nonasthmatic subjects after inhaled LPS challenge with 10,000 EU
CCRE, suggesting that inflammasome function might be impaired in atopic patients.11
IL-1β is produced in response to various inflammatory stimuli and likely plays a central role
in mediating neutrophilic airway responses in human subjects. IL-1β is involved in the
recruitment of airway neutrophils by LPS in murine models31,32 and intratracheal
administration of IL-1 receptor antagonist inhibits LPS-induced airway neutrophilia in
mice.32 Our data indicate that decreased numbers of airway neutrophils recovered from
induced sputum in AA patients after LPS challenge in part might be due to the lack of IL-1β
production by AA patients, although we cannot exclude other factors, such as expression of
intercellular adhesion molecules that regulate chemotaxis to the airways.
This IL-1β response in AA patients was unexpected because recent gene-association studies
have indicated a significant role for IL-1β in asthma.33 In human subjects IL-1β has been
reported to be increased in bronchoalveolar lavage fluid and sputum of asthmatic patients
compared with HVs,34 with airway macrophages from asthmatic patients displaying
increased expression of IL-1β.35 IL-1β levels are also increased in broncho-alveolar lavage
fluid from persons with symptomatic asthma versus those with asymptomatic asthma,36 and
there is increased expression of this cytokine in the airways epithelium of asthmatic
patients.37 We have shown that after ozone exposure, AA patients have increased levels of
sputum IL-1β in their airways, whereas HVs do not.22 However, these differences might be
attributable to the site of injury that triggers the inflammatory response. Most asthma
exacerbations are caused by viral infections that damage the airway epithelium. Ozone
exposure and other agents of environmental pollution also induce epithelial cell oxidative
stress. In contrast, inhaled LPS directly activates airway macrophages through interactions
with TLR4 and CD14. We hypothesize that the initial cellular target of injury might
influence the asthmatic response, with increased inflammation after epithelial cell injury and
reduced inflammation if injury to the epithelium is bypassed.
Leukocytes from atopic asthmatic patients might be less responsive to TLR stimuli
compared with those from nonatopic subjects. Peripheral blood monocytes from atopic
children exhibited reduced upregulation of TLR2 after ex vivo peptidoglycan stimulation
compared with responses from monocytes of nonatopic children.38 Likewise, signaling
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through TLR4 was recently noted to be impaired in CD4+ monocytes derived from atopic
children compared with nonatopic children.39 In adult populations asthmatic patients had
reduced production of TNF-α, IL-10, and IL-1β after ex vivo stimulation by LPS and
flagellin compared with nonasthmatic patients.40 These studies are limited in that PBMCs
might have differential expression of TLRs than those found in the airway, with Juarez et
al41 showing differential responses to various TLR ligands in alveolar macrophages
compared with those seen in peripheral monocytes. After ex vivo LPS exposure, alveolar
macrophages from asthmatic patients (approximately one half were atopic) did not show
significantly increased IL-1β production, whereas those from HVs did.35 It is still unclear
whether airway macrophages from asthmatic patients and other resident leukocytes, such as
eosinophils, are less responsive to TLR activation, thus conferring increased risk to airway
infections. Alternatively, the specific milieu of inflammatory cells that reflect underlying
immune dysregulation, such as the increased eosinophil numbers noted in asthmatic patients
at baseline, might alter responses to infection. In mice infected with Haemophilus
influenzae, it was recently found that those with allergic airways disease had chronic lung
infection compared with nonallergic mice and that airway influx, development of
phagocytosing neutrophils and macrophages, or both were reduced.42 It remains unclear
whether atopic status, asthma status, or both contribute to the increased susceptibility to
airway infections noted in asthmatic patients and which cell types are responsible for this
susceptibility.
In conclusion, although we show that the percentage of neutrophils increases in both HVs
and AA patients after LPS challenge, the absolute numbers of inflammatory cells recruited
to the airway (cells per milligram of sputum) and circulation (cells per deciliter) are
significantly less in AA patients compared with those in HVs. Although we could detect
similar and significant induction of TLR4-MyD88–regulated proinflammatory cytokines,
such as IL-6 and TNF-α, in the sputum supernatants of both groups, AA patients had muted
IL-1β and IL-18 responses to LPS. These data, coupled with those of our prior report, are
consistent with the hypothesis that atopic asthmatic patients have modified innate immune
responses characterized by decreased phagocytic inflammasome function. We hypothesize
that the development of TH2 inflammation results in downregulation of inflammasome
components of phagocytes in atopic subjects. Although the innate immune response is
important in mediating exacerbation of asthma, downregulation of elements of innate
immunity by the TH2 immune response likely contributes to the increased occurrence of
invasive microbial infections observed in this group, as well as changes in microbiome
populations reported in atopic populations that modify asthma severity.
METHODS
Skin prick testing
Atopy was demonstrated by a positive immediate skin test response to one of the following
allergen mixes: 2 species of house dust mite (Dermatophagoides farinae and
Dermatophagoides pteronyssinus), cockroach, tree mix, grass mix, weed mix, mold mix 1,
mold mix 2, rat, mouse, guinea pig, rabbit, cat, or dog. A positive skin test response was
defined as a wheal 3 mm larger than that elicited by the negative saline control.
Sputum induction and processing
For sputum induction, three 7-minute inhalation periods of nebulized hypertonic saline (3%,
4%, and 5%; DeVilbiss UltraNeb 99 ultrasonic nebulizer) were followed by expectoration of
sputum into a sterile specimen cup. A cell-enriched “select” sample was obtained by
selecting visible clumps of cells and cell-rich mucus plugs from the raw sample to separate
them from noncellular portions of the sample. This was then treated with a dilute (0.1%)
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solution of dithiothreitol (Sputolysin; Calbiochem, San Diego, Calif) in Dulbecco PBS to
depolymerize mucins. After centrifugation (500g for 10 minutes), aliquots of sputum
supernatants were immediately frozen and stored at –80°C, and the cell pellet was
suspended in a small volume of Hanks balanced salt solution. Cell viability (trypan blue
exclusion) and total cell counts were assessed by using a Neubauer hemocytometer, and
differential cell counts were performed on cytocentrifuged cells stained with a modified
Wright stain (Hema-Stain-3, Fisher Scientific). Some of the cells were immediately used for
flow cytometric assays.
RESULTS
The primary end point for this study was the %PMN after LPS challenge, with our original
expectation that AA patients would have increased sputum neutrophilia after LPS challenge
compared with HVs. To determine whether we could cease recruitment of AA patients after
enrolling 13 AAvolunteers and 18 HVs, we undertook a conditional power analysis focused
on the differences between post-LPS %PMNs of the 13 AA patients and 18 HVs. Using
procedures outlined for 2-arm trials with arcsin transformationE1 of post-LPS %PMNs to
ensure normal distribution of these data, we calculated a conditional power of 0.9827 based
on the sample pooled SD σ of 0.2403 and sample mean difference at 0.225, suggesting that
continued recruitment of AA patients (assuming similar variation in sputum PMN data)
would not yield a different result. We also undertook a conditional power analysis based on
the postchallenge-prechallenge difference in %PMNs between the HVand AA groups. We
calculated a conditional power close to 0 (2.31E-6) based on the sample pooled SD σ of
28.33 and sample mean difference at 0.5596, suggesting that the study be stopped for futility
if the postchallenge-prechallenge difference in %PMNs was the main end point. These
findings were presented to the NIAID's Data Safety Monitoring Board, and although this
analysis had not been conducted as originally planned, the Data Safety Monitoring Board
granted permission to halt recruitment of additional AA volunteers and proceed with
analysis of all other exploratory end points.
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Abbreviations used
AA Allergic asthmatic
CCRE Clinical Center Reference Endotoxin
eNO Exhaled nitric oxide
EU Endotoxin units
FVC Forced vital capacity
HV Healthy volunteer
NIAID National Institute of Allergy and Infectious Diseases
%PMN Percentage of neutrophils in sputum
TLR Toll-like receptor
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Our findings suggest that AA patients have reduced innate immune airway inflammatory
responses after LPS inhalation compared with HVs. This might increase susceptibility to
infection in AA patients.
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%PMNs in sputum before and after inhaled LPS challenge. %PMNs significantly increased
in both cohorts, with no significant difference in post-LPS–pre-LPS %PMNs between
groups. Lines represent means (n = 18 HVs and 13 AA patients).
Hernandez et al. Page 14














Leukocyte numbers in induced sputum and peripheral blood. Sputum, Absolute numbers of
total leukocytes (cells per milligram, A) and neutrophils (PMNs per milligram, B) in
induced sputum before (pre-LPS) and after (post-LPS) challenge. Blood, Total numbers of
WBCs (C) and PMNs (D) in the blood of HVs and AA patients with LPS challenge. Lines
represent means (n = 18 HVs and 13 AA patients).
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Proinflammatory cytokines recovered from induced sputum. Mean concentrations of TNF-α
(A), IL-6 (B), IL-1β (C), and IL-18 (D) measured in induced sputum supernatants before
LPS and after LPS challenge are shown. Means and SEMs are shown (n = 18 HVs and 12
AA patients).
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Monocyte and macrophage surface marker expression from induced sputum. Monocytes,
Mean fluorescence intensity (MFI) of TLR4 (A) and CD14 (B) before and after LPS
challenge in HVs and AA patients. Macrophages (mΦ), MFI of TLR4 (C), CD14 (D), TLR2
(E), and CD11b (F) before and after LPS challenge. Means with SEMs are shown (n = 13
HVs and 7 AA patients).
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TABLE I
Characteristics of participants
Clinical characteristic HVs AA patients
No. 18 13
Age (y) 24.5 ± 6.4 26.6 ± 8.1
Sex 12 F/6 M 8 F/5 M
Race 13 White 8 White
5 African American 4 African American
1 Asian
BMI (kg/m2) 27.2 ± 6.4 24.3 ± 2.7
Baseline spirometry (% predicted)
    FVC 106.7 ± 11.7 102.1 ± 12.1
    FEV1 102.4 ± 12.6 94.5 ± 11.7
Medications (no. of subjects)
    Antihistamines 0
3
*
    Leukotriene receptor antagonists 0 0
    Nasal steroids 0 0
    Inhaled steroids 0 0
    Short-acting bronchodilator as necessary 0 13
Skin prick test response positivity (no. of subjects)
    Dust mites 0 11
    Trees 0 8
    Grasses 0 9
    Weeds 0 8
    Cat/dog 0 8
    Cockroach 0 4
eNO (nL/min)
    Before LPS 11.9 ± 9.1
66.9 ± 66.2
†
    Six hours after LPS 14.7 ± 11.7 64.3 ± 64.2
Sputum eosinophils/mg
    Before LPS 4.4 ± 7.7
34.4 ± 32.9
†
    Six hours after LPS 11.7 ± 12.0 47.2 ± 73.9
Values are presented as means ± SDs where shown.
BMI, Body mass index; F, female; M, male.
*
Subjects had to be off antihistamines at least 4 days before study procedures.
†
P < .001 comparing baseline eNO levels and eosinophil numbers per milligram in sputum (HVs vs AA patients).
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